Plant stanol ascorbate esters reduce body weight gain through decreased energy absorption in hamsters

International Journal of Obesity

Volumn 30, Issue 5, 2006, Pages 751-757

  Ebine, N ^a   Demonty, I ^a   Jia, X ^a   Jones, P J H ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Body weight; Calorimetry; Intestinal energy absorption; Plant stanol; Plant sterol; Triglycerides

Indexed keywords

DISODIUM ASCORBYL PHYTOSTANYL PHOSPHATE; STANOL ESTER; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CALORIC INTAKE; CALORIMETRY; CHOLESTEROL INTAKE; CONTROLLED STUDY; ENERGY ABSORPTION; ENERGY BALANCE; FECES ANALYSIS; HOMEOSTASIS; HYDROPHILICITY; INTESTINE; MALE; NONHUMAN; PRIORITY JOURNAL; SYRIAN HAMSTER; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ANIMALS; ANTILIPEMIC AGENTS; CALORIMETRY; CHOLESTEROL, DIETARY; CRICETINAE; DIET, REDUCING; EATING; ENERGY METABOLISM; FECES; HYPOLIPIDEMIC AGENTS; INTESTINES; MALE; MESOCRICETUS; OBESITY; PHYTOSTEROLS; RANDOM ALLOCATION; SITOSTEROLS; TRIGLYCERIDES;

ANIMALIA; CRICETINAE; MESOCRICETUS AURATUS;

EID: 33646384165     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0803191     Document Type: Article

References (32)

1. Law MR. Plant sterol and stanol margarine and health. Br Med J 2000; 320: 861-864.
2. Jones PJ, Raeini-Sarjaz M. Plant sterols and their derivatives: the current spread of results. Nutr Rev 2001; 59: 21-24.
3. Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003; 78: 965-978.
4. Ling WH, Jones PJ. Enhanced efficacy of sitostanol-containing versus sitostanol-free phytosterol mixtures in altering lipoprotein cholesterol levels and synthesis in rats. Atherosclerosis 1995; 118: 319-331.
5. Ntanios FY, Jones PJ. Dietary sitostanol reciprocally influences cholesterol absorption and biosynthesis in hamsters and rabbits. Atherosclerosis 1999; 143: 341-351.
6. Lukic T, Wasan KM, Zamfir D, Moghadasian MH, Pritchard PH. Disodium ascorbyl phytostanyl phosphate reduces plasma cholesterol concentrations and atherosclerotic lesion formation in apolipoprotein E-deficient mice. Metabolism 2003; 52: 425-431.
7. Wasan KM, Najafi S, Wong J, Kwong M. Assessing plasma lipid levels, body weight, and hepatic and renal toxicity following chronic oral administration of a water-soluble phytostanol compound, FM-VP4, to gerbils. J Pharm Pharm Sci 2001; 4: 228-234.
8. Wasan KM, Najafi S, Peteherych KD, Pritchard PH. Effects of novel hydrophilic phytostanol analog on plasma lipids concentrations in gerbils. J Pharm Sci 2001; 90: 1795-1799.
9. Ntanios FY, Jones PJ. Effects of variable dietary sitostanol concentrations on plasma lipid profile and phytosterol metabolism in hamsters. Biochim Biophys Acta 1998; 1390: 237-244.
10. Ntanios FY, Jones PJ. Dietary sitostanol reciprocally influences cholesterol absorption and biosynthesis in hamsters and rabbits. Atherosclerosis 1999; 143: 341-351.
11. Vanstone CA, Raeini-Sarjaz M, Jones PJ. Injected phytosterols/stanols suppress plasma cholesterol levels in hamsters. J Nutr Biochem 2001; 12: 565-574.
12. Bieri JG, Stoewsand GS, Briggs GM, Phillips RW, Woodard JC, Knapka JJ. Report of the American Institute of Nutrition ad hoc committee on standards for nutritional studies. J Nutr 1977; 107: 1340-1348.
13. Ostlund Jr RE, McGill JB, Zeng CM, Covey DF, Stearns J, Stenson WF et al. Gastrointestinal absorption and plasma kinetics of soy Delta(5)-phytosterols and phytostanols in humans. Am J Physiol Endocrinol Metab 2002; 282: E911-E916.
14. Kohlmeier M. Direct enzymic measurement of glycerides in serum and in lipoprotein fractions. Clin Chem 1986; 32: 63-66.
15. Meijer GW, Bressers MA, de Groot WA, Rudrum M. Effect of structure and form on the ability of plant sterols to inhibit cholesterol absorption in hamsters. Lipids 2003; 38: 713-721.
16. Rong N, Ausman LM, Nicolosi RJ. Oryzanol decreases cholesterol absorption and aortic fatty streaks in hamsters. Lipids 1997; 32: 303-309.
17. Turley SD, Herndon MW, Dietschy JM. Reevaluation and application of the dual-isotope plasma ratio method for the measurement of intestinal cholesterol absorption in the hamster. J Lipid Res 1994; 35: 328-339.
18. Wasan KM, Peteherych KD, Najafi S. Assessing the plasma pharmacokinetics, tissue distribution, excretion and effects on cholesterol pharmacokinetics of a novel hydrophilic compound, FM-VP4, following administration to rats. J Pharm Pharm Sci 2001; 4: 207-216.
19. Wasan KM, Zamfir C, Pritchard PH, Pederson RA. Influence of phytostanol phosphoryl ascorbate (FM-VP4) on insulin resistance, hyperglycemia, plasma lipid levels, and gastrointestinal absorption of exogenous cholesterol in Zucker (fa/fa) fatty and lean rats. J Pharm Sci 2003; 92: 281-288.
20. Kris-Etherton PM, Dietschy J. Design criteria for studies examining individual fatty acid effects on cardiovascular disease risk factors: human and animal studies. Am J Clin Nutr 1997; 65: 1590S-1596S.
21. Pascot A, Lemieux S, Lemieux I, Prud'homme D, Tremblay A, Bouchard C et al. Age-related increase in visceral adipose tissue and body fat and the metabolic risk profile of premenopausal women. Diabetes Care 1999; 22: 1471-1478.
22. Nakanishi N, Nakamura K, Suzuki K, Matsuo Y, Tatara K. Associations of body mass index and percentage body fat by bioelectrical impedance analysis with cardiovascular risk factors in Japanese male office workers. Ind Health 2000; 38: 273-279.
23. Ostlund Jr RE. Phytosterols in human nutrition. Annu Rev Nutr 2002; 22: 533-549.
24. Moreau RA, Whitaker BD, Hicks KB. Phytosterols, phytostanols, and their conjugates in foods: structural diversity, quantitative analysis, and health-promoting uses. Prog Lipid Res 2002; 41: 457-500.
25. Weiser M, Frishman WH, Michaelson MD, Abdeen MA. The pharmacologic approach to the treatment of obesity. J Clin Pharmacol 1997; 37: 453-473.
26. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003; 27: 1437-1446.
27. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997; 21: S12-S23.
28. Drent ML, van der Veen EA. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes Relat Metab Disord 1993; 17: 241-244.
29. Drent ML, Larsson I, William-Olsson T, Quaade F, Czubayko F, von Bergmann K et al. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord 1995; 19: 221-226.
30. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21: 1288-1294.
31. Tonstad S, Pometta D, Erkelens DW, Ose L, Moccetti T, Schouten JA et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994; 46: 405-410.
32. Mittendorfer B, Ostlund Jr RE, Patterson BW, Klein S. Orlistat inhibits dietary cholesterol absorption. Obes Res 2001; 9: 599-604.